Future Journal of Pharmaceutical Sciences最新文献

筛选
英文 中文
Exploring the potential of SGLT2 inhibitors in Alzheimer’s disease: network pharmacology, molecular docking, and MD simulation study 探索SGLT2抑制剂在阿尔茨海默病中的潜力:网络药理学、分子对接和MD模拟研究
IF 3
Future Journal of Pharmaceutical Sciences Pub Date : 2026-03-16 DOI: 10.1186/s43094-026-00963-2
Roney Miah, Iqrar Ahmad, Mohd Imran, Ammar A. Razzak Mahmood, Mohd Fadhlizil Fasihi Mohd Aluwi
{"title":"Exploring the potential of SGLT2 inhibitors in Alzheimer’s disease: network pharmacology, molecular docking, and MD simulation study","authors":"Roney Miah,&nbsp;Iqrar Ahmad,&nbsp;Mohd Imran,&nbsp;Ammar A. Razzak Mahmood,&nbsp;Mohd Fadhlizil Fasihi Mohd Aluwi","doi":"10.1186/s43094-026-00963-2","DOIUrl":"10.1186/s43094-026-00963-2","url":null,"abstract":"<div><h3>Background</h3><p>Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM) exhibit similar clinical characteristics and are increasingly prevalent in developed countries. Both conditions pose significant public health challenges, prompting research into effective treatments and preventive strategies. This study employs network pharmacology, molecular docking, molecular dynamics (MD) simulations, principal component analysis (PCA), free energy landscape (FEL), molecular mechanics generalized born surface area (MMGBSA) and absorption, distribution, metabolism, excretion, and toxicity (ADMET) and drug-likeness to explore the mechanisms by which sodium-glucose co-transporter-2 (SGLT2) inhibitors may treat AD.</p><h3>Results</h3><p>A comprehensive search identified 1153 targets for SGLT2 inhibitors via SwissTargetPrediction and SuperPred databases, alongside 716 targets for AD from UniProt. The protein–protein interaction (PPI) network highlighted 19 shared targets. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses indicated that the Alzheimer disease signaling pathway (hsa05010), involving proteins such as GSK3B, APP, ADAM10, CAPN1, HSD17B10, and GAPDH, could mediate the effects of SGLT2 inhibitors. Molecular docking studies revealed that canagliflozin binds effectively to glyceraldehyde-3-phosphate dehydrogenase (GAPDH), forming hydrogen bonds with residues Arg11, Asn32, and Arg78, achieving a binding affinity of − 8.9 kcal/mol. Furthermore, 200 ns MD simulations assessed the stability of the canagliflozin–GAPDH complex, analyzing parameters like RMSD, RMSF and hydrogen bonding to elucidate binding interactions. PCA and FEL analyses revealed that canagliflozin occupies a more stable and energetically favorable conformational space, indicating superior dynamic stability compared with rivastigmine system. MMGBSA binding free energy analysis demonstrated that canagliflozin exhibited a significantly stronger binding affinity (− 43.63 ± 5.64 kcal/mol) compared with rivastigmine (− 26.38 ± 5.96 kcal/mol). Furthermore, canagliflozin possesses favorable drug-like features supporting its repurposing potential, further optimization and validation are required to enhance its therapeutic applicability in AD.</p><h3>Conclusion</h3><p>The results suggest that canagliflozin maintains stable interactions with GAPDH, potentially contributing to its potential binding affinity against AD.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00963-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147559458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Navigation of drug discovery via artificial intelligence 通过人工智能导航药物发现
IF 3
Future Journal of Pharmaceutical Sciences Pub Date : 2026-03-09 DOI: 10.1186/s43094-026-00954-3
Saurav Kumar Mishra, J Jeba Praba, Hamadou Mamoudou, Akansha Subba, John J. Georrge
{"title":"Navigation of drug discovery via artificial intelligence","authors":"Saurav Kumar Mishra,&nbsp;J Jeba Praba,&nbsp;Hamadou Mamoudou,&nbsp;Akansha Subba,&nbsp;John J. Georrge","doi":"10.1186/s43094-026-00954-3","DOIUrl":"10.1186/s43094-026-00954-3","url":null,"abstract":"<div><h3>Background</h3><p>The growing global health burden necessitates precise therapeutics to mitigate pathogenesis and severe complications, which are increasing daily. Recently emerging and re-emerging viral infectious diseases, along with other ongoing complications from diverse infections and pathogens, contribute to global outbreaks. To address this, immediate and accurate therapeutic developments that can help manage this crisis are needed. Concerning the development of therapeutics, the conventional method-based drug design is time-consuming and requires a substantial investment of time to develop a drug against the pathogen successfully.</p><h3>Main body of the abstract</h3><p>To overcome these present obstacles, artificial intelligence (AI) came as a hope of revolutionizing the detection and advancement of pioneering, precise, cost- and time-effective drugs. AI uses advanced algorithms to improve the accuracy regarding target identification and further inhibitor selection. The pathogens were re-emerging daily, simultaneously, generating a huge amount of data with various specific properties and other essential details. Among them, some data can be helpful for therapeutic development. Using AI-based pipelines, tools, servers, databases, and useful resources to aid drug discovery, and employing different algorithms to examine the data, it was possible to identify a potential target that could aid therapeutic development; similarly, it also helped revolutionize the clinical aspects of drug discovery and the pharmaceutical industry by enabling more specific data handling. Moreover, it can help utilize available drugs and their significant details to address emerging and ongoing diseases through a drug repurposing-based approach using advanced AI-based computational analysis.</p><h3>Short conclusion</h3><p>Herein, this study offers the AI insight toward the drug discovery and development, how these approaches were utilized, and their advancements and challenges.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00954-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147441278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploratory metaproteomic profiling of the nasal microbiota in a pilot cohort of mothers and infants 探索性元蛋白质组学分析在一个试点队列的母亲和婴儿的鼻腔微生物群
IF 3
Future Journal of Pharmaceutical Sciences Pub Date : 2026-03-04 DOI: 10.1186/s43094-026-00949-0
Samah El-Sayed, Samira Zakeer, Samar Solyman, Salah Abdalla, Amro Hanora, Shymaa Enany
{"title":"Exploratory metaproteomic profiling of the nasal microbiota in a pilot cohort of mothers and infants","authors":"Samah El-Sayed,&nbsp;Samira Zakeer,&nbsp;Samar Solyman,&nbsp;Salah Abdalla,&nbsp;Amro Hanora,&nbsp;Shymaa Enany","doi":"10.1186/s43094-026-00949-0","DOIUrl":"10.1186/s43094-026-00949-0","url":null,"abstract":"<div><h3>Background</h3><p>The nasal passages’ microbial communities are vital to human health and can influence infection processes. In this study, ten nasal samples were obtained, five from mothers and five from their 1- to 2-year-old infants. We studied the proteins of the nasal passage microbiota using the metaproteomic technique. The ten nasal samples collected were initially subjected to in-solution digestion, followed by a series of purification steps to ensure sample quality. Subsequent analysis was performed using LC–MS/MS, and the workflow was finalized with comprehensive data processing and bioinformatic analysis utilizing the UniProt database. The preliminary observations indicated that eight proteins showed differential abundance between the maternal and infant cohorts.</p><h3>Results</h3><p>The eight proteins detected in our exploratory study were found to be of particular importance, as they may be implicated in bacterial pathogenesis, can represent potential drug targets, and may be associated with pathways related to drug resistance. These proteins include amidohydrolase, SLEI domain protein (pf07620 family), histidine kinase (EC 2.7.13.3), RND transporter, GLPGLI family protein, penicillin-binding protein, MFS transporter, and a protein kinase domain-containing protein.</p><h3>Conclusions</h3><p>These observations provide preliminary evidence of how metaproteomics can elucidate the protein interactions within bacterial communities and their interactions with the host, potentially advancing our understanding of infection processes and guiding the development of targeted therapies.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00949-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147363054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-time sensing approaches and antibiofilm strategies for biofilm-associated infections: advances and perspectives on medical devices and clinical contexts 生物膜相关感染的实时传感方法和抗生素膜策略:医疗设备和临床环境的进展和观点
IF 3
Future Journal of Pharmaceutical Sciences Pub Date : 2026-03-02 DOI: 10.1186/s43094-026-00944-5
Darshita Valde, Tukendra Kumar, Satya Eswari Jujjavarapu
{"title":"Real-time sensing approaches and antibiofilm strategies for biofilm-associated infections: advances and perspectives on medical devices and clinical contexts","authors":"Darshita Valde,&nbsp;Tukendra Kumar,&nbsp;Satya Eswari Jujjavarapu","doi":"10.1186/s43094-026-00944-5","DOIUrl":"10.1186/s43094-026-00944-5","url":null,"abstract":"<div><h3>Background</h3><p>Biofilms are communities of microorganisms encased in a self-produced extracellular matrix. They can form on living hosts or in the environment, and a diverse range of microbes participate in this process. These include harmful bacteria that can become reservoirs for chronic infections. Biofilms contribute to a broad spectrum of illnesses and the emergence of antibiotic resistance, making infections difficult to treat.</p><p>Biofilms are communities of microorganisms encased in a self-produced extracellular matrix. They can form on living hosts or in the environment, and a diverse range of microbes participate in this process. These include harmful bacteria that can become reservoirs for chronic infections. Biofilms contribute to a broad spectrum of illnesses and the emergence of antibiotic resistance, making infections difficult to treat.</p><h3>Main body of the abstract</h3><p>Biofilm growth is most common on medical devices. Real-time detection and development of antibiofilm drugs are crucial to prevent related infections and ensure human health. This review explores infectious diseases associated with both medical and non-medical devices in humans. Furthermore, advanced detection approaches such as impedimetric, potentiometric, surface acoustic waves, and optical fiber sensors, which tackle the real-time growth of bacterial biofilms, are discussed. Additionally, various strategies to combat bacterial biofilm growth on medical devices are also examined. The future direction of research is also explored, focusing on the disadvantages and limitations of sensors and antibiofilm approaches.</p><h3>Short conclusion</h3><p>In this review, we found that the most powerful and easy-to-use sensing approach is impedimetric biosensor. Additionally, the commonly used antibiofilm approach involves nanoparticle-based drug coating on medical devices. Comprehensively, this review covers all possible directions of sensing approaches and antibiofilm strategies, addressing their challenges and potential solutions.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00944-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147335724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of methods for detecting ciprofloxacin in pharmaceuticals and urine: UV–Vis spectrophotometry versus poly ([Mn(Chr)3]Cl2)/PGE voltammetry 药物和尿液中环丙沙星检测方法的比较:紫外-可见分光光度法与聚([Mn(Chr)3]Cl2)/PGE伏安法
IF 3
Future Journal of Pharmaceutical Sciences Pub Date : 2026-02-27 DOI: 10.1186/s43094-026-00948-1
Abebaw Shitahun Ayicheh, Minaleshewa Atlabachew, Belete Asefa Aragaw, Amare Benor, Bamlaku Abebaw, Atakilt Abebe
{"title":"Comparison of methods for detecting ciprofloxacin in pharmaceuticals and urine: UV–Vis spectrophotometry versus poly ([Mn(Chr)3]Cl2)/PGE voltammetry","authors":"Abebaw Shitahun Ayicheh,&nbsp;Minaleshewa Atlabachew,&nbsp;Belete Asefa Aragaw,&nbsp;Amare Benor,&nbsp;Bamlaku Abebaw,&nbsp;Atakilt Abebe","doi":"10.1186/s43094-026-00948-1","DOIUrl":"10.1186/s43094-026-00948-1","url":null,"abstract":"<div><h3>Background</h3><p>Ciprofloxacin (Cpro) is a drug belonging to the fluoroquinolones class which can contribute to bacterial resistance due to its improper and overuse, and excretion in urine as unchanged. Therefore, continuous monitoring is required. In this work, voltammetric technique with pencil graphite electrode (PGE) modified by manganese(II)-chrysin complex ([Mn(Chr)<sub>3</sub>]Cl<sub>2</sub>) has been developed and its performance has been compared with the unmodified PGE working electrode and UV–Vis spectrophotometric method.</p><h3>Results</h3><p>Both the developed and UV–Vis spectrophotometric methods were calibrated using a series of standard solutions of Cpro with increasing concentration in the range of 1–250 µM. After calibrating the two methods, Cpro has been determined in two brands of pharmaceuticals, in urine samples, and in the presence of paracetamol. The values of dynamic range, LoD, and sensitivity for the developed method were 1–250 µM, 0.536 µM, and 0.148, respectively, whereas in UV–Vis spectrophotometric method the dynamic range, LoD, and sensitivity were 1–120 µM, 0.413 µM, and 0.025, respectively.</p><h3>Conclusion</h3><p>Based on slope value, dynamic range, and selectivity the developed method has better performance than UV–Vis spectrophotometric method.</p><h3>Graphical abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00948-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147342459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pracaxi oil (Pentaclethra macroloba)-loaded nanofibers: a promising biomaterial for wound healing 大叶草油负载纳米纤维:一种有前途的伤口愈合生物材料
IF 3
Future Journal of Pharmaceutical Sciences Pub Date : 2026-02-26 DOI: 10.1186/s43094-026-00938-3
Eduardo Ricci-Júnior, Luana Santos Monteiro, Ana Carolina Souza de Lima, Anna Lecticia Martinez Martinez Toledo, Marcos Lopes Dias, Tatiana Almeida Pádua, Thadeu Estevam Moreira Maramaldo Costa, Francisco Paiva Machado, Mikaela Amaral Ferreira, Leandro Machado Rocha, Elaine Cruz Rosas, Mariana Sato de Souza Bustamante Monteiro
{"title":"Pracaxi oil (Pentaclethra macroloba)-loaded nanofibers: a promising biomaterial for wound healing","authors":"Eduardo Ricci-Júnior,&nbsp;Luana Santos Monteiro,&nbsp;Ana Carolina Souza de Lima,&nbsp;Anna Lecticia Martinez Martinez Toledo,&nbsp;Marcos Lopes Dias,&nbsp;Tatiana Almeida Pádua,&nbsp;Thadeu Estevam Moreira Maramaldo Costa,&nbsp;Francisco Paiva Machado,&nbsp;Mikaela Amaral Ferreira,&nbsp;Leandro Machado Rocha,&nbsp;Elaine Cruz Rosas,&nbsp;Mariana Sato de Souza Bustamante Monteiro","doi":"10.1186/s43094-026-00938-3","DOIUrl":"10.1186/s43094-026-00938-3","url":null,"abstract":"<div><h3>Background</h3><p>Chronic and complex wounds remain a significant clinical challenge, requiring biomaterials that can provide structural support and bioactive signaling. <i>Pentaclethra macroloba</i> (Pracaxi) oil is recognized for its regenerative properties; its integration into advanced delivery systems, such as electrospun nanofibers, which offer high surface area and mimic extracellular matrix, remains unexplored. This work aimed to develop and characterize poly(lactic acid) (PLA) nanofibers loaded with Pracaxi oil (OP) as an innovative bioactive dressing for wound healing.</p><h3>Methods</h3><p>The chemical profile of OP was determined by gas chromatography-mass spectrometry (GC–MS). PLA/OP nanofibers (1%–20% w/w) were produced via electrospinning process and characterized by scanning electron microscopy (SEM), X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FTIR), and thermal analysis (DSC/TGA). Biological performance was evaluated using human keratinocyte (HaCaT) viability (MTT assay) and cell migration (scratch assay).</p><h3>Results</h3><p>CG-MS identified 11 fatty acids (98.95%), with oleic acid (50.93%) and behenic acid as the primary bioactive component. OP incorporation influenced fiber diameter and induced the formation of beads, which reduced the mat porosity. The oil acted as a plasticizer, slightly decreasing the glass transition temperature (Tg) and thermal stability, while the amorphous structure of PLA was preserved. Nanofibers containing up to 15% w/w of OP demonstrated excellent biocompatibility, with cell viability exceeding 100%. The 15% w/w of OP formulation was identified as the optimal system, significantly accelerating keratinocyte migration compared to pure PLA and control groups (<i>p</i> &lt; 0.01).</p><h3>Conclusions</h3><p>This study successfully integrated OP into PLA nanofibers for the first time. The resulting membrane combines the structural advantages of nanofibers with the therapeutic benefits of PO. Specifically, the 15% w/w formulation is a promising biomimetic scaffold for wound healing. Future in vivo studies are suggested to confirm these findings.</p><h3>Graphical abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00938-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147341893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A comprehensive review on ethnobotany, phytochemistry, traditional and modern uses of chasteberry (Vitex agnus-castus L.) 蔓越莓(Vitex agnus-castus L.)的民族植物学、植物化学、传统和现代应用综述
IF 3
Future Journal of Pharmaceutical Sciences Pub Date : 2026-02-23 DOI: 10.1186/s43094-025-00931-2
Shaza H. Aly, Noha N. Nasr, Riham A. El-Shiekh, Shymaa Hatem, Youssef Hashem Hafez, Amr Bahr, Menna A. Alsadany, Mohamed S. Abd El Hafeez, Abdel-Aziz S. Shatat, Nehal Mohamed Eisa, Rana M. Merghany
{"title":"A comprehensive review on ethnobotany, phytochemistry, traditional and modern uses of chasteberry (Vitex agnus-castus L.)","authors":"Shaza H. Aly,&nbsp;Noha N. Nasr,&nbsp;Riham A. El-Shiekh,&nbsp;Shymaa Hatem,&nbsp;Youssef Hashem Hafez,&nbsp;Amr Bahr,&nbsp;Menna A. Alsadany,&nbsp;Mohamed S. Abd El Hafeez,&nbsp;Abdel-Aziz S. Shatat,&nbsp;Nehal Mohamed Eisa,&nbsp;Rana M. Merghany","doi":"10.1186/s43094-025-00931-2","DOIUrl":"10.1186/s43094-025-00931-2","url":null,"abstract":"<div><p><i>Vitex agnus-castus</i> L. (chaste tree) has a rich history of use in traditional medicine across various cultures for over 2500 years, particularly for gynecological issues. Its applications range from regulating menstrual cycles to alleviating premenstrual syndrome and menopausal symptoms, with endorsements from health authorities such as the German Commission E. This review aims to consolidate existing knowledge on the ethnopharmacological uses, phytochemistry, and pharmacological effects of <i>V. agnus-castus</i>, while also discussing its safety profile and therapeutic potential. The relevant articles were identified by searching PubMed (www.pubmed.com), Scopus (http://www.scopus.com), ISI Web of Science (www.webofknowledge.com), and Google Scholar (www.scholar.google.com) up to November 2024. <i>V. agnus-castus</i> exhibits a wide range of pharmacological properties, including antioxidant, anti-inflammatory, antimicrobial, and cytotoxic effects. Its active compounds, particularly casticin, have been linked to these benefits. Future research should focus on advanced preclinical and clinical studies to better assess its safety and therapeutic efficacy in diverse populations.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-025-00931-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147341096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic potential of rutamarin: preclinical evidence of its biological properties through in silico, in vitro, and in vivo studies 芦叶黄素的治疗潜力:通过计算机、体外和体内研究证明其生物学特性的临床前证据
IF 3
Future Journal of Pharmaceutical Sciences Pub Date : 2026-02-19 DOI: 10.1186/s43094-026-00945-4
Shafinah Ahmad Suhaimi, Khairunnisa’ Md Yusof, Norazalina Saad
{"title":"Therapeutic potential of rutamarin: preclinical evidence of its biological properties through in silico, in vitro, and in vivo studies","authors":"Shafinah Ahmad Suhaimi,&nbsp;Khairunnisa’ Md Yusof,&nbsp;Norazalina Saad","doi":"10.1186/s43094-026-00945-4","DOIUrl":"10.1186/s43094-026-00945-4","url":null,"abstract":"<div><h3>Background</h3><p>In traditional medicine, natural compounds, such as coumarins, have been recognised as effective therapeutic agents for a variety of ailments. One of the natural furanocoumarins is rutamarin, which can be abundantly found in the Rutaceae family. It has been demonstrated to possess diverse biological properties in preclinical models, underscoring its potential for therapeutic applications in various health problems.</p><h3>Main body</h3><p>This review provides an extensive description and critical evaluation of the biological activities of rutamarin, particularly anticancer, antidepressant, antidiabetic, and antimicrobial effects. To a lesser extent, the antinociceptive, antivenom, and antiviral effects of rutamarin are also included. Scientific preclinical evidence based on in silico, in vitro, and in vivo models is discussed, highlighting its potential as a pharmaceutical agent for therapeutic purposes. As a natural product, the distribution and chemical extraction of rutamarin in plants, as well as its isolation, are also discussed. Moreover, efforts to amplify the yield of rutamarin in in vitro plant cultures and to synthesise rutamarin are briefly described. Since most studies previously utilised in silico analysis to elucidate rutamarin’s mechanism of action, limitations and future directions for clinical trials are also suggested.</p><h3>Conclusion</h3><p>Advancement to clinical trials is a crucial step towards utilising rutamarin as a therapeutic agent for various diseases and health complications, including cancers, diabetes, and microbial infections. However, current findings that largely rely on in silico and in vitro models need further preclinical validation of the biological properties, especially in vivo models, which are essential prior to advancement to clinical setting.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00945-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147340505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Repurposing baricitinib and/or rosuvastatin to reinvigorate the anticancer immune response via suppressing PD-1/PD-L1 and CTLA-4 inhibitory immune checkpoints and correlated oncogenic pathways in lung cancer models 巴西替尼和/或瑞舒伐他汀通过抑制肺癌模型中PD-1/PD-L1和CTLA-4抑制免疫检查点和相关致癌途径来重振抗癌免疫反应
IF 3
Future Journal of Pharmaceutical Sciences Pub Date : 2026-02-18 DOI: 10.1186/s43094-026-00937-4
Sara Muhammad El-Hanboshy, Ihab T. Abdel-Raheem, Maged Wasfy Helmy
{"title":"Repurposing baricitinib and/or rosuvastatin to reinvigorate the anticancer immune response via suppressing PD-1/PD-L1 and CTLA-4 inhibitory immune checkpoints and correlated oncogenic pathways in lung cancer models","authors":"Sara Muhammad El-Hanboshy,&nbsp;Ihab T. Abdel-Raheem,&nbsp;Maged Wasfy Helmy","doi":"10.1186/s43094-026-00937-4","DOIUrl":"10.1186/s43094-026-00937-4","url":null,"abstract":"<div><h3>Background</h3><p>Lung cancer is the prime cause of cancer-related death worldwide. It is an aggressive malignant tumor characterized by significant dysregulation of various oncogenic and immunosurveillance pathways. STAT3 is considered to be a point of convergence of such pathways, so it is an attractive therapeutic target for lung cancer. Hence, the current study aimed to investigate the anticancer activity of baricitinib and/or rosuvastatin as repurposed drugs known to inhibit STAT3.</p><h3>Methods and results</h3><p>In vitro experiments were conducted using two NSCLC cell lines (A549 and H460), and the MTT test was used to assess the cytotoxic activity of both drugs and their combination. Moreover, selected oncogenic proteins were quantified. In addition, in vivo experiments were also performed using a urethane-induced lung cancer mice model. Both drugs showed excellent anticancer activities along with outstanding synergism when combined. Baricitinib and/or rosuvastatin inhibited cancer cell proliferation, migration, and angiogenesis in addition to inducing apoptosis. Furthermore, they exhibited immunoediting effects against cancer via significant suppression of PD-L1 and CTLA-4 inhibitory immune checkpoints.</p><h3>Conclusion</h3><p>The current study highlights the potential therapeutic benefits of baricitinib as an anticancer agent, for the first time, and/or rosuvastatin as repurposed drugs that can be used in lung cancer treatment.</p><h3>Graphical abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div><p>Created in BioRender.\u0000El-hanboshy, S. (2025) https://BioRender.com/l95u186.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00937-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147339806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmaceutical nanotechnology research in Egypt: prospects in treatment of liver diseases, patenting, and regulatory implications 埃及的药物纳米技术研究:治疗肝病的前景、专利申请和监管影响
IF 3
Future Journal of Pharmaceutical Sciences Pub Date : 2026-02-17 DOI: 10.1186/s43094-026-00942-7
Maha Nasr, Ahmed M. Kabel, Fatma S. Abdel-Salam, Nadia M. Hamdy
{"title":"Pharmaceutical nanotechnology research in Egypt: prospects in treatment of liver diseases, patenting, and regulatory implications","authors":"Maha Nasr,&nbsp;Ahmed M. Kabel,&nbsp;Fatma S. Abdel-Salam,&nbsp;Nadia M. Hamdy","doi":"10.1186/s43094-026-00942-7","DOIUrl":"10.1186/s43094-026-00942-7","url":null,"abstract":"<div><h3>Background</h3><p>The application of nanotechnology in the biomedical field has greatly expanded in the last decade, as delineated by the large number of publications by several researchers. Particularly for liver diseases which are prevalent in Egypt, published research has delineated that nanotechnology-based products were able to enhance the therapeutic efficacy and safety of drugs, by modulating their distribution and pharmacokinetic properties, protecting them from degradation, reducing their renal clearance and elimination, enhancing liver specific uptake and targeting, and overcoming mechanisms of drug resistance. However, surveying the granted patents in this regard displayed the limited number of patents, concurring with limited availability of nanotechnology-based products in the market.</p><h3>Areas covered</h3><p>This review article firstly details the research conducted in Egypt for treatment of prevalent liver diseases using nanotechnology-based products, then details the granted patents in Egypt and internationally in this regard, followed by an overview on the existing safety and regulatory implications, and recommendations for their improvement, in order to increase the number of commercially available products in the market.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00942-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147339539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书